[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Rijeka\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":188},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,80,105,136,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100601137","phase-1-safety-and-efficacy-of-lyophilized-fecal-microbiota-transplantation-via-capsules-for-intestinal-multidrug-resistant-bacteria-decolonization-100601137",false,"NCT07106580","Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Via Capsules for Intestinal Multidrug-resistant Bacteria Decolonization","A Monocentric, Prospective, Randomized, Placebo-controlled, Double-blinded Trial Investigating the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Capsules in Decolonization of Patients With Intestinal Carriage of Multidrug-resistant Organisms","FORCE","Inclusion Criteria:\n\n* ≥ 18 years,\n* stool sample or rectal swab positive for MDRO (CRE, ESBL-E, VRE) within a week of randomization,\n* capable of swallowing oral capsules,\n* willing to give informed consent\n\nExclusion Criteria:\n\n* antibiotic treatment on the day of inclusion,\n* pregnant or breastfeeding, women of childbearing potential who are unwilling or unable to use an acceptable method of birth control,\n* patients with terminal diseases with expected life expectancy \\\u003C 6 months,\n* unwillingness to ingest the capsules,\n* a history of colectomy, present colostomy or ileostomy,\n* patients with the diagnosis\u002Ftreatment of inflammatory or functional bowel disease,\n* patients with malignant bowel diseases,\n* absolute neutrophil count \\\u003C 500\u002Fmm3,\n* selective digestive decolonization with antibiotics within 6 months before randomization,\n* severe allergy to capsule components","ALL","18 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of this clinical trial is to learn if oral capsules containing lyophilized stool from healthy donors (fecal microbiota transplantation or FMT) can safely and effectively decolonize multidrug-resistant organisms (MDROs) from the intestines in adults. The main questions it aims to answer are:\n\n1. Does FMT via oral capsules reduce or eliminate intestinal MDRO colonization?\n2. What side effects or adverse events occur after taking FMT capsules?\n\nResearchers will compare FMT capsules to placebo capsules to see if FMT is effective and safe for decolonizing MDROs.\n\nParticipants will:\n\n* Take either FMT capsules or placebo capsules by mouth\n* Attend 4 follow-up study visits over 6 months (180 days) for microbiological testing and safety monitoring\n* Provide stool samples and report any side effects",[28],"Colonization, Asymptomatic",[30,31,32,33,34,35],"FMT","Fecal microbiota transplantation","Colonization","MDRO","Multidrug-resistant bacteria","Lyophilization","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":40},"2025-07-28",{"date":44,"type":21},"2027-09",{"name":46,"class":47},"University of Rijeka","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100626127","prognostic-value-of-sii-and-siri-in-obesity-related-metabolic-complications-100626127","NCT07431593","Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications","Clinical Significance and Prognostic Value of Systemic Immune Inflammation Index and Systemic Inflammation Response Index in Obesity and Associated Metabolic Complications","SIMO-PRO","Inclusion Criteria\n\n* Age ≥ 18 years\n* BMI 25.0-29.9 kg\u002Fm² (overweight) or BMI ≥ 30 kg\u002Fm² (obesity)\n* Ability to attend scheduled clinical visits\n* Willingness to provide informed consent\n\nExclusion Criteria\n\n* Pregnancy or breastfeeding\n* Use of immunosuppressive therapy\n* Active infection\n* Inflammatory disease\n* Malignancy\n* Acute illness affecting immune parameters\n* Conditions interfering with study participation (as assessed by the investigator)\n* Known hematologic disorders affecting leukocyte or platelet counts\n* Chronic inflammatory diseases requiring systemic therapy\n* Recent major surgery (within the last 3 months)\n* Any condition that could confound the relationship between SII\u002FSIRI and obesity-driven inflammation, such as immune disorders",true,{"count":59,"type":21},200,"OBSERVATIONAL","This observational study aims to evaluate the diagnostic and prognostic value of the systemic immune-inflammatory index (SII) and the systemic inflammation response index (SIRI) in individuals with overweight or obesity. The study will assess their association with obesity status, metabolic complications, lifestyle patterns, dietary indices, and established inflammatory biomarkers. Participants will undergo anthropometric assessment, laboratory testing, dietary evaluation, and follow-up for response to different obesity treatment modalities over 3 years. The study intends to determine whether SII and SIRI can serve as clinically useful predictors of metabolic risk and treatment outcomes of obesity.",[63,64,65],"Overweight and Obesity","Inflammation","Metabolic Syndrome",[67,68,69,70,71],"obesity","overweight","Systemic Immune Inflammatory Index (SII)","Systemic Inflammation Response Index (SIRI)","inflammation","2026-04-30",{"date":74,"type":40},"2026-05-07",{"date":76,"type":21},"2026-04",{"date":78,"type":21},"2027-12-31",{"name":46,"class":47},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100629957","phase-1-safety-and-efficacy-of-lyophilized-faecal-microbiota-transplantation-via-capsules-in-treatment-of-irritable-bowel-syndrome-100629957","NCT07481422","Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome","LYO-IBS","Inclusion Criteria:\n\n* 18-65 years of age\n* disease activity defined by an IBS-Symptom Severity Score (IBS-SSS) of more than 175\n* symptoms refractory to conservative medical therapy (hyoscine salts, osmotic laxatives such as polyethylene glycol, loperamide, rifaximin, tricyclic antidepressants, SSRIs or other antidepressants, peppermint oil)\n* negative evaluation for coeliac disease\n* signed informed consent\n\nExclusion Criteria:\n\n* pregnant or breastfeeding women\n* women of childbearing potential who are unwilling to use an acceptable method of birth control\n* severely immunocompromised or immunosuppressed (organ transplant recipients, those with neutropenia with an absolute neutrophil count of \\\u003C500 cells per mm3, those receiving current treatment with antineoplastic drugs, HIV positive)\n* gastrointestinal symptoms explained by an alternative diagnosis (underlying IBD, infectious enteritis)\n* severe allergy to capsule components\n* therapy with new antidepressants or had a change in antidepressant dose within previous 3 months\n* serious medical comorbidities (including neurological or psychiatric comorbidities)\n* treatment with antibiotics 3 months before enrolment\n* previous history of FMT at any time in the past\n* unwillingness to ingest the capsules","65 Years",{"count":89,"type":21},70,[24,25],"The goal of this clinical trial is to learn if oral capsules containing lyophilized fecal microbiota transplantation (FMT) can safely and effectively treat refractory irritable bowel syndrome (IBS) in adults aged 18-65 years. The main questions it aims to answer are:\n\nDoes treatment with lyophilized FMT capsules reduce IBS symptom severity compared with placebo?\n\nDoes treatment with lyophilized FMT capsules improve quality of life, anxiety, and depression in patients with IBS?\n\nAre there differences in the frequency of adverse events between participants receiving FMT capsules and those receiving placebo?\n\nResearchers will compare lyophilized FMT capsules to placebo capsules to see if FMT reduces IBS symptoms and improves quality of life and mental health.\n\nParticipants will:\n\nBe randomly assigned to receive either lyophilized FMT capsules or placebo capsules for three consecutive days.\n\nTake the capsules under supervision after receiving a proton pump inhibitor before the first dose.\n\nComplete questionnaires assessing symptom severity, quality of life, anxiety, and depression at baseline, 4 weeks, and 12 weeks after treatment.\n\nAttend follow-up visits at 4 weeks and 12 weeks after treatment and receive a telephone follow-up call 10 days after capsule ingestion.\n\nReport any adverse events and have vital signs and medical information monitored during follow-up.\n\nThis study will help determine whether oral lyophilized FMT capsules are a safe and effective treatment option for adults with refractory IBS.",[93],"Irritable Bowel Syndrome (IBS)",[30,95,96,35],"Irritable Bowel Syndrome","IBS","2026-03-13",{"date":99,"type":40},"2026-03-18",{"date":101,"type":21},"2026-03-15",{"date":103,"type":21},"2027-12-15",{"name":46,"class":47},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":113,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":48},"100587208","changes-in-natural-immunity-in-pregnant-women-with-autoimmune-thyroid-disease-100587208","NCT06925399","Changes in Natural Immunity in Pregnant Women With Autoimmune Thyroid Disease","Dynamic Changes of Innate Immune Cells in Pregnant Women With Autoimmune Thyroid Disease","CIPAT","Inclusion Criteria: adult healthy pregnant women and pregnant women with autoimmune thyroid disease\n\n* with a single pregnancy\n* older than 18 years\n* who have signed the informed consent form\n\nExclusion Criteria:\n\n* pregnant women who refuse to give informed consent\n* pregnant women under the age of 18\n* pregnant women with malignant diseases\n* pregnant women with thyrotoxicosis or hypothyroidism of a non-autoimmune nature and previous thyroidectomy or ablative therapy with iodine-131\n* pregnant women with an acute or chronic disease that is not an autoimmune thyroid disease","FEMALE","45 Years",{"count":116,"type":21},80,"Autoimmune thyroid disease (AITD) is the most common endocrine disorder in women of reproductive age, including during pregnancy. It encompasses two clinical conditions: autoimmune hyperthyroidism and hypothyroidism. Pregnancy significantly affects thyroid function regulation, while thyroid dysfunction can influence fertility, pregnancy progression, and the postpartum health. Although the role of acquired immunity in AITD is well understood, recent research increasingly emphasizes innate immunity. Key cells involved in innate immunity include neutrophils, monocytes, and NKT cells. However, limited data exist on their role during pregnancy, especially in women with AITD.\n\nThis study aims to investigate the dynamic changes in neutrophils, monocytes and NKT cells during pregnancy and compare findings between women with normal pregnancies and those with AITD.\n\nThe study will analyze the frequency and activation status of these innate immune cells in peripheral blood samples collected during the first, second, and third trimesters. In addition, concentrations of thyrotropin, thyroid hormones, thyroglobulin, and thyroid autoantibodies, will be measured. A thyroid ultrasound will also be performed.",[119,120],"Pregnancy","Autoimmune Thyroid Disease",[119,122,123,124,125,126],"Autoimmune thyroid disease","Innate immunity","NKT cells","Monocytes","Neutrophils","NOT_YET_RECRUITING","2025-04-06",{"date":130,"type":40},"2025-04-13",{"date":132,"type":21},"2025-05-01",{"date":134,"type":21},"2027-05-01",{"name":46,"class":47},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":48},"100571880","3d-characteristics-functional-appliances-and-sleep-related-breathing-disorders-100571880","NCT06726005","3D Characteristics, Functional Appliances and Sleep Related Breathing Disorders","Impact of Functional Appliances on 3D Craniodentofacial Characteristics and Reported Sleep Related Breathing Disorders in Children","FA PSQ HR","Inclusion Criteria:\n\n* retrognathic mandible, increased overjet\n\nExclusion Criteria:\n\n* craniodentofacial deformities","10 Years","14 Years",{"count":147,"type":21},20,[149],"NA","Facial scans of the patients eligible for the functional appliance treatment (Twin Block appliance) will be taken prior to and after the end of treatment. Also, a facial scan of the predicted final outcome will be taken, and compared to the actual final outcome. Parents \u002F caregivers will fill out the Pediatric Sleep Questionnaire (PSQ) prior to and upon the end of treatment to asses perceived influence on sleep related breathing problems in their children.",[152],"Retrognathic Mandible",[154,155,156],"PSQ","Twin block","3D facial scan","2024-12-05",{"date":159,"type":40},"2024-12-10",{"date":161,"type":40},"2024-04-08",{"date":163,"type":21},"2027-07",{"name":46,"class":47},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":57,"sex":17,"minAge":173,"maxAge":18,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":187,"locationsCount":48},"100571878","effect-of-the-palatal-expansion-treatment-on-reported-sleeping-disorders-in-children-100571878","NCT06725979","Effect of the Palatal Expansion Treatment on Reported Sleeping Disorders in Children","Effect of the Rapid Palatal Expansion Treatment on Reported Sleeping Disorders in Children","RPE PSQ HR","Inclusion Criteria:\n\nnarrow maxilla\n\nExclusion Criteria:\n\nhypodontia, craniodentofacial deformity-","2 Years",{"count":147,"type":21},[149],"The goal of this clinical trial is to see if expanding the upper jaw with orthodontic therapy can help improve sleep related breathing problems in children. Parents or caregivers will complete the Pediatric Sleep Questionnaire (PSQ) to assess their child's sleep before and after treatment.\n\nThe study will include 20 children with a narrow upper jaw, and a control group of children without this condition. The main questions it aims to answer are:\n\n* Will the 3D scans show significant changes in the face after therapy?\n* Will the dental scans show a larger palate volume after treatment?\n* Will parents\u002Fcaregivers notice an improvement in their children's sleep problems after therapy? Researchers will compare 3D facial and dental scans, as well as PSQ results, before and one year after therapy to see if the treatment makes a difference.\n\nParticipants will:\n\n* Receive orthodontic treatment to expand the upper jaw.\n* Have their sleep related breathing problems assessed by parents or caregivers using the PSQ before and after treatment.\n* Have 3D scans of their face and teeth taken before and after treatment.",[178],"Narrow Maxilla",[180,154,181,182,183],"palatal expansion","facial scan","orthodontics","hyrax expander",{"date":159,"type":40},{"date":161,"type":40},{"date":163,"type":21},{"name":46,"class":47},""]